Department of Human Pathology, Wakayama Medical University, Wakayama City, Japan.
Cancer Sci. 2011 Jan;102(1):288-94. doi: 10.1111/j.1349-7006.2010.01769.x. Epub 2010 Nov 10.
There is a continuous debate regarding the classification of thyroid follicular lesions and the term "well-differentiated tumor of uncertain malignant potential (WDT-UMP)" was recently introduced to cover this problematic spectrum of tumors. The objective of this study was to reappraise WDT-UMP using morphological, immunochemical, and molecular analysis and to shed more light on encapsulated thyroid follicular-patterned tumors. A total of 30 cases of WDT-UMP with equivocal papillary thyroid carcinoma-type nuclear changes (PTC-N) or focal unequivocal PTC-N were examined. As a control, follicular adenoma (n = 29), follicular carcinoma (n = 8), hyalinizing trabecular adenoma (n = 5), and PTC (n = 48) were included. HBME-1, cytokeratin 19, and galectin-3 were positive in 12 (40.0%), 10 (33.3%) and 11 (36.7%) cases of WDT-UMP, respectively. According to the positivity of those markers, significant differences were obtained between WDT-UMP and PTC encapsulated common type (P = 0.028, 0.010, and 0.004, respectively), infiltrative follicular variant (P = 0.020, 0.026, and 0.008, respectively), and infiltrative common type (P = 0.004, 0.001, and 0.005, respectively), but not between WDT-UMP and follicular adenoma or follicular carcinoma. BRAF(V600E) mutation was absent but RET/PTC1 rearrangement was found in only two (6.7%) cases of WDT-UMP. None of the 20 patients with WDT-UMP developed recurrence, with an average follow-up of 80 months. These findings indicate that WDT-UMP has a favorable outcome and is distinct from PTC in morphological, immunohistochemical, and molecular characteristics. We propose that WDT-UMP should be classified as "well-differentiated tumor with uncertain behavior".
关于甲状腺滤泡性病变的分类一直存在争议,最近引入了“分化良好的恶性潜能不确定肿瘤(WDT-UMP)”一词来涵盖这一具有问题的肿瘤谱。本研究的目的是通过形态学、免疫化学和分子分析重新评估 WDT-UMP,并进一步阐明包膜性甲状腺滤泡模式肿瘤。共检查了 30 例具有可疑甲状腺乳头状癌型核改变(PTC-N)或局灶性明确 PTC-N 的 WDT-UMP。作为对照,包括滤泡性腺瘤(n=29)、滤泡癌(n=8)、玻璃样小梁性腺瘤(n=5)和 PTC(n=48)。WDT-UMP 中 HBME-1、细胞角蛋白 19 和半乳糖凝集素-3 分别阳性 12(40.0%)、10(33.3%)和 11(36.7%)例。根据这些标志物的阳性率,WDT-UMP 与 PTC 包膜普通型(P=0.028、0.010 和 0.004)、浸润滤泡变体(P=0.020、0.026 和 0.008)和浸润普通型(P=0.004、0.001 和 0.005)之间存在显著差异,但与滤泡性腺瘤或滤泡癌之间无差异。WDT-UMP 中未发现 BRAF(V600E)突变,但仅在 2 例(6.7%)中发现 RET/PTC1 重排。20 例 WDT-UMP 患者均未复发,平均随访 80 个月。这些发现表明 WDT-UMP 具有良好的预后,在形态学、免疫组织化学和分子特征上与 PTC 不同。我们建议将 WDT-UMP 归类为“具有不确定行为的分化良好的肿瘤”。